Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed ... 12, 2024 ...

Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 ...

The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...

Our commitment to innovation and technological leadership keeps us at the forefront of ADC development. We continuously invest in new technologies and expand our manufacturing capabilities, including ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Torrent Pharmaceuticals Ltd.'s consolidated net profit rose 17% in the second quarter of the current financial year, missing analysts' estimates. The company posted a net profit of Rs 453 crore in the ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

“We want to support your ADC development,” said Ann, a spokesperson for Huateng Pharma. “Our high-purity PEGs are designed to meet the specific requirements of your formulations, ensuring ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...